CRISPR-Cas9 and Immunotherapy for Cancer
DOI:
https://doi.org/10.54097/kkqxb693Keywords:
Cancer; CRISPR-Cas9; Immunotherapy.Abstract
Genome editing is part of the key research topics today. Researchers found, that the system of CRISPR-Cas9 can use Cas9 protein to manipulate the actual gene parts, playing a genuine editing role. Nowadays, the system of CRISPR-Cas9 is using widely in many area, like the cultivation of genetically modified crops, industrial production and the treatment for illness and so on. Except for those, the CRISPR-Cas9 system can be also with other method like immunotherapy to achieve the treatment in different types of cancers. In the development of specific cancer, they achieve continuous proliferation by capturing the host immune checkpoint. With the aberrant expression of PD1 in cancer cells, they achieve immune evasion through interaction between PD1 and PD-L1, which are currently the target of cancer treatment. This paper utilize the treatment of non-small-cell as an example to expound the knockout of PD-1 by CRISPR-Cas9 system, artificially constructed T-cell can keep activating T-cell proliferation.
Downloads
References
[1] JHUNJHUNWALA S, HAMMER C, DELAMARRE L. Antigen presentation in cancer: Insights into tumour immunogenicity and immune evasion [J]. Na- ture Reviews Cancer, 2021,21(5):298-312.
[2] LI X S, LI J W, LI H, et al. Prognostic value of pro- crammed cell death ligand 1 (PD-L1) for hematocele- vulvar carcinoma: a meta-analysis [J]. Bioscience Re- ports, 2020,40(4): BSR20200459.
[3] BLANK C U, HAINING W N, HELD W, et al. Defi- ning ‘T-cell exhaustion’[J]. Nature Reviews Immu- ology, 2019,19(11):665-674.
[4] PHILIP M, FAIRCHILD L, SUN L, et al. Chromatin states define tumour - specific T-cell dysfunction and reprogramming [J]. Nature, 2017,545(7655):452- 456.
[5] JIMBU L, MESAROS O, NEAGA A, et al. The po-tential advantage of targeting both PD-L1 / PD-L2 / PD -1 and IL-10 – IL-10R pathways in acute myeloid leukemia [J]. Pharmaceuticals, 2021,14(11):1105.
[6] Jennifer A. Doudna et al. Diverse virus-encoded CRISPR-Cas’s systems include streamlined genome editors Cell,2022, 185(24): 4574-4586.
[7] You Lu et al.Safety and feasibility of CRISPR-edited Tcells in patients with refractory non-small-cell lung cancer Nature medicine,2020,0845(5):732-740
[8] Hakim Manghwar et al.CRISPR/Cas Systems in Genome Editing:Methodologies and Tools for sgRNA Design,Off-Target Evaluation,and Strategies to Mitigate Off-Target Effects Advanced Science,2020,7(6)：1902312
[9] Bao XR,Pan Y et al.Tools for experimental and computational analyses of off target editing by programmable nucleases Nature protocols,2021,16(1):10-26
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
